Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial
Purpose: Alopecia areata (AA), an autoimmune disorder characterized by non-scarring hair loss, is detrimental to the psychological health and quality of life of people living with AA. Clinically meaningful hair regrowth is possible, but the relationship with downstream patient-reported outcomes (PRO...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2460577 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542552506499072 |
|---|---|
| author | Ernest H. Law Kent A. Hanson Matthew Harries Dane Korver Bintu Sherif Costel Chirila |
| author_facet | Ernest H. Law Kent A. Hanson Matthew Harries Dane Korver Bintu Sherif Costel Chirila |
| author_sort | Ernest H. Law |
| collection | DOAJ |
| description | Purpose: Alopecia areata (AA), an autoimmune disorder characterized by non-scarring hair loss, is detrimental to the psychological health and quality of life of people living with AA. Clinically meaningful hair regrowth is possible, but the relationship with downstream patient-reported outcomes (PROs) is complex.Materials and methods: This post hoc analysis of ALLEGRO-2b/3 (NCT03732807) longitudinal data from Weeks 24–48 compared improvements in PROs between patients who achieved (responders) or did not achieve (non-responders) clinically meaningful scalp hair regrowth. Responders were defined by a Week 24 Severity of Alopecia Tool (SALT) score ≤20 (SALT20) or ≤10 (SALT10). Across 6 PROs assessing multiple AA-related health domains, response proportions and mean changes from baseline were estimated for Weeks 24–48.Results: Among 650 included participants, 114 (17.5%) were SALT20 responders, of which 76 (11.7%) were also SALT10 responders. Generally, more responders than non-responders reported improvements in AA and related symptoms or limitations and satisfaction with hair regrowth. Responders additionally reported greater improvement from baseline than non-responders for measures of AA-related emotional symptoms, mental health, and work or activity limitations.Conclusions: These results support a positive relationship between scalp hair regrowth and downstream PROs—including satisfaction and psychosocial burden—demonstrating an association between clinically meaningful hair regrowth and patient-reported treatment benefits. |
| format | Article |
| id | doaj-art-f54f1d0640604cc9bdabfe41476794fd |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-f54f1d0640604cc9bdabfe41476794fd2025-02-04T00:47:51ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2460577Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trialErnest H. Law0Kent A. Hanson1Matthew Harries2Dane Korver3Bintu Sherif4Costel Chirila5Pfizer Inc, New York, NY, USAPfizer Inc, New York, NY, USASalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UKRTI Health Solutions, NC, USARTI Health Solutions, NC, USARTI Health Solutions, NC, USAPurpose: Alopecia areata (AA), an autoimmune disorder characterized by non-scarring hair loss, is detrimental to the psychological health and quality of life of people living with AA. Clinically meaningful hair regrowth is possible, but the relationship with downstream patient-reported outcomes (PROs) is complex.Materials and methods: This post hoc analysis of ALLEGRO-2b/3 (NCT03732807) longitudinal data from Weeks 24–48 compared improvements in PROs between patients who achieved (responders) or did not achieve (non-responders) clinically meaningful scalp hair regrowth. Responders were defined by a Week 24 Severity of Alopecia Tool (SALT) score ≤20 (SALT20) or ≤10 (SALT10). Across 6 PROs assessing multiple AA-related health domains, response proportions and mean changes from baseline were estimated for Weeks 24–48.Results: Among 650 included participants, 114 (17.5%) were SALT20 responders, of which 76 (11.7%) were also SALT10 responders. Generally, more responders than non-responders reported improvements in AA and related symptoms or limitations and satisfaction with hair regrowth. Responders additionally reported greater improvement from baseline than non-responders for measures of AA-related emotional symptoms, mental health, and work or activity limitations.Conclusions: These results support a positive relationship between scalp hair regrowth and downstream PROs—including satisfaction and psychosocial burden—demonstrating an association between clinically meaningful hair regrowth and patient-reported treatment benefits.https://www.tandfonline.com/doi/10.1080/09546634.2025.2460577Alopecia areatapatient-reported outcomesscalp hair regrowthsatisfactionclinical responder |
| spellingShingle | Ernest H. Law Kent A. Hanson Matthew Harries Dane Korver Bintu Sherif Costel Chirila Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial Journal of Dermatological Treatment Alopecia areata patient-reported outcomes scalp hair regrowth satisfaction clinical responder |
| title | Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial |
| title_full | Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial |
| title_fullStr | Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial |
| title_full_unstemmed | Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial |
| title_short | Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial |
| title_sort | patient reported outcome improvements following scalp hair regrowth among patients with alopecia areata analysis of the allegro 2b 3 trial |
| topic | Alopecia areata patient-reported outcomes scalp hair regrowth satisfaction clinical responder |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2025.2460577 |
| work_keys_str_mv | AT ernesthlaw patientreportedoutcomeimprovementsfollowingscalphairregrowthamongpatientswithalopeciaareataanalysisoftheallegro2b3trial AT kentahanson patientreportedoutcomeimprovementsfollowingscalphairregrowthamongpatientswithalopeciaareataanalysisoftheallegro2b3trial AT matthewharries patientreportedoutcomeimprovementsfollowingscalphairregrowthamongpatientswithalopeciaareataanalysisoftheallegro2b3trial AT danekorver patientreportedoutcomeimprovementsfollowingscalphairregrowthamongpatientswithalopeciaareataanalysisoftheallegro2b3trial AT bintusherif patientreportedoutcomeimprovementsfollowingscalphairregrowthamongpatientswithalopeciaareataanalysisoftheallegro2b3trial AT costelchirila patientreportedoutcomeimprovementsfollowingscalphairregrowthamongpatientswithalopeciaareataanalysisoftheallegro2b3trial |